KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ambev (ABEV) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Ambev (ABEV) over the last 14 years, with Q3 2025 value amounting to $1.9 billion.

  • Ambev's Cost of Revenue fell 609.71% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 billion, marking a year-over-year decrease of 218.54%. This contributed to the annual value of $7.5 billion for FY2024, which is 468.79% down from last year.
  • Latest data reveals that Ambev reported Cost of Revenue of $1.9 billion as of Q3 2025, which was down 609.71% from $1.8 billion recorded in Q2 2025.
  • In the past 5 years, Ambev's Cost of Revenue registered a high of $2.2 billion during Q4 2024, and its lowest value of $1.5 billion during Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $1.9 billion (2022), whereas its average is $1.9 billion.
  • As far as peak fluctuations go, Ambev's Cost of Revenue skyrocketed by 3831.79% in 2021, and later crashed by 1002.46% in 2023.
  • Quarter analysis of 5 years shows Ambev's Cost of Revenue stood at $1.9 billion in 2021, then increased by 10.97% to $2.1 billion in 2022, then fell by 10.02% to $1.9 billion in 2023, then increased by 14.7% to $2.2 billion in 2024, then fell by 13.77% to $1.9 billion in 2025.
  • Its Cost of Revenue was $1.9 billion in Q3 2025, compared to $1.8 billion in Q2 2025 and $1.9 billion in Q1 2025.